NCT05705466View on ClinicalTrials.gov

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Navtemadlin

Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.

DRUG

Navtemadlin Placebo

Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.

DRUG

Pembrolizumab

Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously

Sponsors
All Listed Sponsors
lead

Kartos Therapeutics, Inc.

INDUSTRY

NCT05705466 - Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter